Rapidly increasing off-label use of rituximab in multiple sclerosis in Sweden - Outlier or predecessor?

The share of MS patients in Sweden who are treated with rituximab is very high, and also rapidly increasing. Taken into account the off-label use, cases with adverse medical conditions that could possibly be related to rituximab use should be reported thoroughly.